Bio-rad Laboratories Inc (BIO) Q2 2019 10-Q Quarterly Earnings

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q2 2019 10-Q quarterly report on Aug 6, 2019 for the quarter ended Jun 30, 2019.

AI summary of MD&A and risk factor updates

Q2 revenue $572.6M, down 0.6% YoY from $575.9M, currency-neutral growth 2.7%
Gross margin 53.7% vs 52.4% YoY; net income 104.6% of sales vs 46.5%
Best segment Clinical Diagnostics: revenue $357.1M, up 0.9% YoY; worst Life Science: $212.4M, down 2.5%
Cash, cash equivalents and short-term investments $981.9M; operating cash flow $198.3M for six months vs $118.2M
Capital deployment: $15.0M share repurchase, $45.8M capital expenditures, $20.0M acquisition; headwinds from government spending, trade disputes and regulation

ERP deployment risk: April 2019 Western Europe implementation could disrupt product availability, shipments, invoicing and payments
Regulatory compliance risk: Mexican regulator COFEPRIS cited Bio-Rad’s subsidiary, potentially restricting Clinical Diagnostics operations until resolved
Competitive risk: Multi-year public tenders intensified pricing pressure and reduced annual tender opportunities
Currency risk: Foreign entities generated 60% of net sales, exposing results to U.S. dollar strengthening
Debt risk: $439.4 million outstanding indebtedness and $200.0 million revolving capacity as of June 30, 2019

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.